

Scientific Program

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00

Thursday, October 7

Chair Persons: T. Grundström, D.W. Felsher, H. Yoshikawa

- 246. Regulatory mechanisms controlling somatic hypermutation. J. Hauser, J. Verma-Gaur, A. Wallenius, **T. Grundström** (Umeå, Sweden) (30')
- 208. Modeling and predicting oncogene addiction. **D.W. Felsher** (Stanford, CA, USA) (30')
- 178. Inhibition of cancer-specific CpG island methylation for suppression of cancer. **H. Yoshikawa** (Tokyo, Japan) (30')
- 177. mRNA stability and its role in biomedical sciences. **I. Morozov**, M.X. Caddick (Liverpool, UK) (30')

SIGNAL TRANSDUCTION

Room A, 11:30-13:00

Thursday, October 7

Chair Persons: A.P. Fields, J.D. Altenburg

- 182. Protein kinase C α regulates the intracellular localization and oncogenic activity of ECT2 through direct phosphorylation. **A.P. Fields**, V. Justilien (Jacksonville, FL, USA) (30')
- 183. aPKCs in pancreatic cancer. M.L. Scotti, A.M. Butler, A.P. Fields, **N.R. Murray** (Jacksonville, FL, USA) (30')
- 164. Omega-3 fatty acid regulation of chemokine signaling in cancer and heart disease. **J.D. Altenburg**, K. Harvey, J. van Horne, R. Siddiqui (Indianapolis, IN, USA) (30')

CELL CYCLE/CANCER BIOLOGY

Room A, 16:00-17:30
Thursday, October 7

Chair Persons: N.A.P. Franken, Z.H. Siddik, L. Vodickova

123. Inhibition of homologous recombination by mild hyperthermia shunts early double strand break repair to non-homologous end-joining in G2 phase cells. J.W.J. Bergs, P.M. Krawczyk, R. ten Cate, H. Rodermond, T. Borovski, J.P. Medema, J. Aten, **N.A.P. Franken** (Amsterdam, The Netherlands) (30')
207. The paradox in cell cycle effects of cisplatin: Failure of tumor cells to accumulate in G1 following activation of G1-checkpoint. G. He, J. Kuang, A.R. Khokhar, **Z.H. Siddik** (Houston, TX, USA) (30')
311. DNA repair gene expressions in cancer patients and in individuals exposed to chemical carcinogens. **L. Vodickova**, M. Hanova, R. Vaclavikova, R. Stetina, I. Hlavata, M. Ehrlichová, D. Kovar, P. Soucek, P. Vodicka (Prague, Czech Republic) (30')

SIGNALING/MOLECULAR ONCOLOGY

Room A, 18:00-19:30
Thursday, October 7

Chair Persons: N. Duesbery, H.M. Said, R. Ketteler

136. Signaling through the mitogen-activated protein kinase kinases is necessary for developmental and pathologic neo-vascularization. **N. Duesbery**, J. Bromberg-White, E. Boguslawski (Grand Rapids, MI, USA) (30')
272. Active modulation of hypoxia induced human brain cancer regulative genes. **H.M. Said**, C.T. Supuran, C. Hagemann, J. Anacker, A. Staab, M. Flentje, D. Vordermark (Wuerzburg; Halle, Germany; Florence, Italy; Zürich, Switzerland) (30')
305. High-throughput screening approaches to dissect cancer signaling pathways. **R. Ketteler** (London, UK) (30')

EXPERIMENTAL ONCOLOGY/PHARMACOLOGY

Room B, 09:00-11:00
Thursday, October 7

Chair Persons: J. Rudner, C. Sato, A. Di Pietro

229. Novel strategies targeting Bcl-2 family members in tumor cells. **J. Rudner** (Tuebingen, Germany) (30')
312. Analysis of oxidative stress sensor Keap1 protein using single particle reconstruction and ASEM. T. Ogura, K. Mio, Y. Maruyama, H. Nishiyama, M. Suga, **C. Sato** (Ibaraki, Japan) (30')
340. Selective modulators of multidrug-resistant cancer cell ABCG2 and ABCC1 transporters: *In vitro* ligand-based drug design and *in vivo* validation. **A. Di Pietro** (Lyon, France) (30')
130. Analysis of mitotic spindle checkpoint function in human malignant gliomas. **C. Hagemann**, A. Kessler, B. Polat, R. Patel, R.-I. Ernestus, G.H. Vince (Würzburg, Germany; Leicester, UK) (30')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:00
Thursday, October 7

Chair Persons: B. Jezersek Novakovic, N. Latruffe, G.P. Stathopoulos

128. The intensity of CD20 expression determines the outcome of rituximab treatment. **B. Jezersek Novakovic**, M. Horvat, V.K. Prevodnik, S. Novakovic (Ljubljana, Slovenia) (30')
101. Characterization of new cell targets to resveratrol: A cancer chemopreventive agent. **N. Latruffe**, F. Mazué, D. Colin, D. Delmas (Dijon, France) (15')
108. Plasma VEGF in breast cancer patients with and without metastases. J. Stathopoulos, A. Armacolas, **G.P. Stathopoulos**, I.P. Gomatos (Athens, Greece) (15')
150. Anti-neuroblastoma activity of saquinavir in association with the tyrosine kinase inhibitor imatinib: Molecular mechanisms. **F. Timeus**, N. Crescenzo, E. Lupino, A. Doria, L. Foglia, S. Pagliano, E. Ricotti, B. Buccinnà, C. Ramondetti, M.T. Rinaudo, P.-A. Tovo, M. Piccinini, L.C. Di Montezemolo (Turin, Italy) (15')
159. Clinical pilot study with a novel radiolabeled vitamin B12 derivative for detection of neoplastic tissue. **R. Waibel**, N. Schäfer, I. Burger, L. von Boehmer, E. Nexo, A.P. Schubiger, R. Schibli (Villigen; Zurich, Switzerland; Aarhus, Denmark) (15')

MOLECULAR BIOLOGY/IMMUNOLOGY

Room B, 16:00-17:30
Thursday, October 7

Chair Persons: B.A. Bryan, L. Vannucci, N. Jahroudi

247. Targeting the cytoskeleton in tumors. **B.A. Bryan** (Worcester, MA, USA) (30')
187. Cancer microenvironment: Structural changes, NK cells, and the inflammatory tumor network. **L. Vannucci**, L. Arana, J. Krizan, V. Grobarova, A. Fiserova, P. Rossmann, K. Klimesova, V. Ullmanova-Benson, M. Burocziova, O. Chernyavskiy, J. Klepetar, P. Vodicka, L. Lipska (Prague, Czech Republic; Bilbao, Spain) (30')
309. Organ-specific distribution of NFI isoforms participate in organ-specific regulation of VWF promoter. **N. Jahroudi** (Edmonton, Canada) (30')

APOPTOSIS/MOLECULAR ONCOLOGY

Room B, 18:00-19:30
Thursday, October 7

Chair Persons: E. Gavathiotis, L.A. Stark

262. Dissecting and targeting the activation pathway of BAX to re-activate apoptosis in cancer. **E. Gavathiotis**, D.R. Ruiz, M.L. Davis, G.H. Bird, L.D. Walensky (Boston, MA, USA) (30')
285. Nucleolar targeting of NF- κ B/RelA and apoptosis. N. Khandewal, J. Simpson, G. Taylor, S. Rafique, C. Clarke, J. Hiscox, **L.A. Stark** (Edinburgh; Leeds, UK) (30')
220. Pro apoptotic properties of a novel polybisphosphonate. **A.R. Holmberg**, U.H. Lerner, A. Alaiya, M. Al-Mohanna, C. Adra, M. Marquez, L. Meurling, S. Nilsson (Stockholm; Umeå; Gothenburg, Sweden; Riyadh, Saudi Arabia) (15')
148. The DNA minor groove alkylating agent S23906-1 destabilizes the DNA helix: Molecular mechanism of action, cellular and anti-tumor consequences. **M.-H. David-Cordonnier** (Lille, France) (15')

BRAIN TUMORS

Room C, 09:00-11:00
Thursday, October 7

Chair Persons: J.S. Yakisich, A. Sedo, T. Kondo

201. Perspectives on preclinical drug evaluation for anticancer drug with special emphasis on gliomas. **J.S. Yakisich**, D. Avramidis, Z. Delwar, Å. Siden, M. Cruz (Stockholm, Sweden) (30')
205. Dipeptidyl peptidase-IV in gliomagenesis. **A. Sedo**, J. Nemeckova, E. Balaziová, P. Busek, D. Kosek, M. Hilser, K. Vlasicova (Prague, Czech Republic) (30')
226. Induced glioma-initiating cell models reveal novel therapeutic targets. **T. Kondo**, T. Hide, T. Takezaki, Y. Nakatani, H. Nakamura, J. Kuratsu (Kobe; Toon; Kumamoto, Japan) (20')
230. Multidrug resistance-inducing effects of environmental endocrine disruptors in human neuroblastoma SK-N-SH cells. **X. Xiao**, H. Zhu, J. Zheng, S. Zheng, K. Dong, J. Liu, Y. Wang (Shanghai, P.R. China) (20')
231. The effect of di-2-ethylhexyl phthalate on human neuroblastoma cells. **H. Zhu**, X. Xiao, S. Zheng, Y. Wang (Shanghai, P.R. China) (20')

MOLECULAR ONCOLOGY

Room C, 11:30-13:00
Thursday, October 7

Chair Persons: S. Heinsohn, A. Komiya, A. Di Carlo

175. Are SV40 and p53 team players in childhood B-ALL and B-NHL? **S. Heinsohn**, R. Scholz, H. Kabisch (Hamburg, Germany) (30')
232. Neuroendocrine differentiation in the progression of prostate cancer. **A. Komiya**, A. Watanabe, K. Yasuda, K. Ichimatsu, H. Fuse (Toyama, Japan) (30')
171. Evaluation of matrix-metalloproteinases (MMPs) in the urine of patients with cancer. **A. Di Carlo**, A. Mariano, V. Macchia (Rome; Naples, Italy) (15')
176. *O*-GlcNAcylation of cellular proteins in thyroid cancer cells. **A. Krzeslak**, P. Józwiak, A. Lipinska (Lodz, Poland) (15')

IMMUNOLOGY/MOLECULAR ONCOLOGY

Room C, 16:00-17:30
Thursday, October 7

Chair Persons: T. van Hall, M. Slevin

341. A novel category of tumor antigens enable CTL immunity to tumor escape variants. **T. van Hall** (Leiden, The Netherlands) (30')
353. P35/Cdk5: Two critical players in cytoskeletal/cell junction stability in human brain endothelial cell angiogenesis. A. Bosutti, R. Pennucci, S. Matou, J. Gaffney, S. Love, L.-H. Tsai, K.P. Giese, S. Kumar, J. Krupinski, **M. Slevin** (Manchester; Bristol; London, UK; Cambridge, MA, USA; Milano, Italy; Barcelona, Spain) (30')
338. Neutrophil elastase promotes lung tumor growth. **A. McGarry Houghton** (Pittsburgh, PA, USA) (30')

MOLECULAR ONCOLOGY/PHARMACOLOGY

Room C, 18:00-19:30
Thursday, October 7

Chair Persons: R. Veselska, A. Gutsche

234. Enhancement of retinoid-induced cell differentiation in cancer therapy. **R. Veselska**, M. Redova, P. Chlapek, K. Zitterbart, M. Hermanova, J. Sterba (Brno, Czech Republic) (30')
203. *In vitro* testing of a new class MMP-I in a co-cultivation model of cholangiocarcinoma cells with human gallbladder fibroblasts. **A. Gutsche**, H. Tschesche, H.-P. Bruch, M.-L. Kruse, M. Kapischke (Aschersleben; Bielefeld; Luebeck; Kiel; Hamburg, Germany) (15')
102. Evaluating drug efficacy in bladder cancer cell lines. **R. Pinto-Leite**, L. Santos, P.A. Oliveira (Vila Real; Porto, Portugal) (15')
134. Anemia of cancer: Molecular mechanisms involved in TNFalpha-mediated inhibition of erythropoiesis. C. Grigorakaki, **F. Morceau**, M. Dicato, M. Diederich (Luxembourg) (15')
355. Influence of high intracellular zinc on prostate cancer cells growth and transcriptional responses. **P.-F. Wong**, S. Abubakar (Kuala Lumpur, Malaysia) (15')

MOLECULAR MEDICINE

Room D, 09:00-11:00
Thursday, October 7

Chair Persons: K. Ohlendieck, V.S. Lalioti, K. Mio

106. Mass spectrometry-based proteomic profiling of neuro-muscular disorders. L. Staunton, C. Lewis, S. Carberry, E. Mullen, **K. Ohlendieck** (Kildare, Ireland) (30')
121. Amfion, a novel gene implicated in nuclear envelope and Golgi remodelling. **V.S. Lalioti**, S. Vergarajauregui, D. Pulido, M. Goethals, J. Vandekerckhove, I.V. Sandoval (Madrid; Barcelona, Spain; Gent, Belgium) (30')
276. Depiction of 3D structure and assignment of functional subunits of membrane proteins using a transmission electron microscopy. **K. Mio**, T. Ogura, Y. Maruyama, M. Mio, C. Sato (Tokyo, Japan) (30')
188. ZnuA, the soluble component of the bacterial Zn(II) ABC transporter, a possible target for novel antibiotics. F. Alaleona, R. Di Santo, E. Chiancone, **A. Ilari** (Rome, Italy) (30')

MOLECULAR MEDICINE

Room D, 11:30-13:00
Thursday, October 7

Chair Persons: N.E. Burgis, P.E. Nagao, W.J. Malaisse

144. The P32T variant of human ITPase is functional *in vitro* and *in vivo*. **N.E. Burgis**, G. Herting, K. Barber, M.R. Zappala, R.P. Cunningham (Cheney, WA; Albany, NY, USA) (25')
251. Molecular aspects in the pathogenesis of neonatal group B streptococcal infections. **P.E. Nagao** (Rio de Janeiro, Brazil) (25')
149. Alteration of the insulin secretory response to extracellular hypoosmolarity and to D-glucose in pancreatic islets from aquaglyceroporin 7-knock-out mice. **W.J. Malaisse**, K. Louchami, E. Hupkens, R. Beauwens, A. Sener (Brussels, Belgium) (20')
259. Loss of Hnf1alpha leads to mTOR signalling stimulation and intestinalomegaly in mice. C. Lussier, F. Brial, C. Jones, N. Rivard, **F. Boudreau** (Sherbrooke, Canada) (20')

MOLECULAR MEDICINE

Room D, 16:00-17:30
Thursday, October 7

Chair Persons: T.-H. Chuang, I. Di Liegro, P. Fishman

166. Role of Hsp90 molecular chaperone in control of Toll-like receptor activation. **T.-H. Chuang**, C. Xu, J. Liu (La Jolla, CA, USA; Miaoli County, Taiwan) (30')
179. RNA-binding CSD-C2 protein and its interactors in nerve cell differentiation. C.M. Di Liegro, P. Saladino, P. Proia, G. Schiera, G. Palazzolo, A. Lo Cicero, **I. Di Liegro** (Palermo, Italy) (30')
198. CF101 for the treatment of autoimmune inflammatory diseases: Data from phase 2 clinical trials in patients with rheumatoid arthritis, psoriasis and dry eye syndrome. **P. Fishman**, S. Bar-Yehuda (Petach-Tikva, Israel) (30')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room D, 18:00-19:30
Thursday, October 7

Chair Persons: T. Takahashi, A. Orzechowski, M.-J. Boucher

185. Exhaled carbon monoxide concentration: A possible marker of oxidative stress. **T. Takahashi** (Okayama, Japan) (30')
189. Lipid rafts are platforms to combine survival and death signals 'Live fast and die hard'. S. Orzechowska, B. Pajak, B. Gajkowska, **A. Orzechowski** (Warsaw, Poland) (30')
243. The glycogen synthase kinase-3 plays critical roles in the proliferation and survival of human pancreatic cancer cells. B. Marchand, **M.-J. Boucher** (Sherbrooke, Canada) (30')

EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00
Friday, October 8

Chair Persons: J.A. McCubrey, L.S. Steelman, S. Emanuele

151. Targeting cancer stem cells - Lancing their Achilles heel. **J.A. McCubrey**, W.H. Chappell, S. Abrams, A.M. Martelli, F. Stivala, F. Nicoletti, M. Donia, M. Libra, M. Cervello, L.S. Steelman (Greenville, NC, USA; Bologna; Catania; Palermo, Italy) (30')
152. Roles of proliferative and metastatic pathways in chemotherapeutic drug resistance and cancer stem cells-sites for therapeutic intervention. **L.S. Steelman**, R. Kempf, J. Long, W.H. Chappell, S. Abrams, A.M. Martelli, F. Stivala, F. Nicoletti, M. Donia, M. Libra, M. Cervello, J.A. McCubrey (Greenville, NC, USA; Bologna; Catania; Palermo, Italy) (30')
233. Anti tumor action of the natural compound parthenolide. D. Carlisi, **S. Emanuele**, A. D'Anneo, M. Lauricella, L. Angileri, R. Vento, G. Tesoriere (Palermo, Italy) (30')
113. Cancer invasion proteome: Integrative preclinical and translational studies for molecular understanding and therapeutic targeting. **M. Alaoui-Jamali** (Montreal, Canada) (30')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:00
Friday, October 8

Chair Persons: Y.M. Rustum, Z. Ghorab, R. Kappler

119. Hypoxia-inducible factor-1 regulation and therapeutic implication. **Y.M. Rustum** (Buffalo, NY, USA) (30')
107. An immunohistochemical update on targeted therapy determinants. **Z. Ghorab** (Toronto, Canada) (30')
194. The hedgehog signaling pathway as a therapeutic target in pediatric liver tumors. M. Eichenmüller, I. Gruner, B. Hagl, D. von Schweinitz, **R. Kappler** (Munich, Germany) (15')
361. Normally developing polyploidy is associated with senescence, while tetraploidy induced by Aurora-B promotes tumorigenesis. H.H. Nguyen, D. Yang, D. Chinnappan, **K. Ravid** (Boston, MA, USA) (15')

EXPERIMENTAL THERAPEUTICS

Room A, 15:00-16:30
Friday, October 8

Chair Persons: A.V. Salnikov, J. Prakash, W. Walther

195. Overexpression of TRAIL in lymphocytes enhances therapeutic efficacy of bispecific EpCAMxCD3 antibody against pancreatic cancer stem cells. **A.V. Salnikov**, A. Groth, E. Ryschich, M.W. Büchler, I. Herr, G. Moldenhauer (Heidelberg, Germany) (30')
211. Targeting of anticancer agents to tumor stroma using PDGF-beta receptor binding carrier: A novel approach to treat cancer. **J. Prakash**, E. De Jong, E. Post, L. Beljaars, K. Poelstra (Groningen, The Netherlands) (30')
241. Novel approach for targeted cancer gene therapy using the *Clostridium perfringens* enterotoxin (CPE). **W. Walther**, S. Petkov, O.N. Bölling, D. Kobelt, J. Aumann, U. Stein, P.M. Schlag (Berlin, Germany) (30')

MOLECULAR ONCOLOGY/TUMOR BIOLOGY

Room A, 17:00-18:30
Friday, October 8

Chair Persons: P.E. Nielsen, K.H. Dragnev, M. Jhanwar-Uniyal

261. Biomolecular drug delivery by peptides, peptidomimetics and polyamines. A peptide nucleic acid (PNA) perspective in gene targeting. **P.E. Nielsen** (Copenhagen, Denmark) (30')
275. Combination therapy targeting G1 cyclins is active against lung cancers harboring K-ras mutations. **K.H. Dragnev**, T. Ma, F. Galimberti, V. Memoli, J.R. Rigas, D. Johnstone, C. Erkmen, W. Nugent, S.J. Freemantle, S. Waxman, E. Dmitrovsky (Lebanon, NH; Hanover, NH; New York, NY, USA) (30')
306. Understanding molecular mechanism of cancer metastasis to the brain. **M. Jhanwar-Uniyal** (Valhalla, NY, USA) (30')

APOPTOSIS/THERAPEUTICS

Room B, 09:00-11:00
Friday, October 8

Chair Persons: D.E. Gomez, Y. Suzuki

135. Novel perioperative treatment strategies: The case of desmopressin (DDAVP). **D.E. Gomez**, G.V. Ripoll, J. Garona, N.B. Iannucci, D.F. Alonso (Buenos Aires, Argentina) (30')
156. Persistent plasma membrane depolarization sensitizes human cancer cells to TRAIL-induced apoptosis. **Y. Suzuki**, T. Inoue, M. Murai, M. Tochigi, M. Suzuki-Karasaki, T. Ochiai, C. Ra (Tokyo, Japan) (30')
335. A new concept of drug delivery system in oncology. **Y. Matsumura** (Kashiwa, Japan) (20')
158. Effect of millimeter wave on the differentiation, proliferation and apoptosis of chondrocytes. **J. Peng**, X. Li, M. Wu, M. Du, G. Wu, H. Ye, W. Chen, J. Lin, X. Liu (Fujian; Fuzhou, P.R. China) (20')
160. The tumor tissue renin-angiotensin system as a target for cancer therapy. **W.J. Petty**, A.A. Miller, M. Aklilu, T.P. McCoy, C.B. Swift, F.M. Torti (Winston-Salem, NC, USA) (20')

CANCER THERAPEUTICS/SIGNALING

Room B, 11:30-13:20
Friday, October 8

Chair Persons: E. Agostinelli, S. Doxsey, W. Sun

367. Lysosomotropic compounds and docetaxel sensitize cancer cells to enzymatic spermine metabolites: A new approach in tumour therapy. **E. Agostinelli**, G. Tempera, N. Viceconte, S. Saccoccio, E. Bidollari, M. Condello, A. Molinari (Rome, Italy) (20')
370. Midbodies accumulate in stem cells and putative cancer stem cells. T.-C. Kuo, C.-T. Chen, D. Baron, **S. Doxsey** (Worcester, MA, USA) (20')
218. Involvement of anoikis in the process of hepatoma metastasis and the strategy on the gene therapy. **W. Sun**, L. Han, Z. Zhang, L. Cao, Y. Liu (Jinan, P.R. China) (20')
219. Anoikis resistance in metastatic hepatoma cells and key molecular screening. **L. Cao**, L. Han, Z. Zhang, W. Sun (Jinan, P.R. China) (15')
154. Human RNASET2 mediates tumor suppression by means of *in vivo* recruitment of stromal cells. **F. Acquati**, S. Bertilaccio, L. Monti, A. Grimaldi, R. Cinquetti, M. Lualdi, P. Bonetti, P. Ghia, F. Sanvito, C. Doglioni, C. Riva, C. Capella, D. Noonan, A. Sica, R. Taramelli (Varese; Milan; Rozzano, Italy) (15')
372. Regulation of EGFR signaling by the E3 ubiquitin ligase Nedd4-1. Q. Lin, J. Wang, C. Childress, M. Sudol, D.J. Carey, **W. Yang** (Danville, PA, USA) (20')

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room B, 15:00-16:30
Friday, October 8

Chair Persons: M.K. Cherukuri, O.-G. Issinger

139. Magnetic resonance imaging of tumor oxygen status *in vivo*. **M.K. Cherukuri**, J.B. Mitchell (Bethesda, MD, USA) (30')
109. Hypericin, a selective inhibitor of the catalytic subunit of protein kinase CK2. K. Nöske, E. Brunstein, T. Rasmussen, K. Niefind, **O.-G. Issinger** (Odense, Denmark; Cologne, Germany) (20')
165. Mitochondrial targeting improves the efficacy of respiratory chain-specific anti-cancer compounds. **L.-F. Dong**, V.J.A. Jameson, M. Coster, S.J. Ralph, R.A.J. Smith, J. Neuzil (Queensland, Australia; Dunedin, New Zealand; Prague, Czech Republic) (20')
131. Epigenetic silencing of glutathione *S*-transferase P1 gene expression in human leukemia. **M. Schnekenburger**, T. Karius, J. Walter, M. Dicato, M. Diederich (Luxembourg; Saarbrücken, Germany) (20')

MOLECULAR ONCOLOGY

Room B, 17:00-18:30
Friday, October 8

Chair Persons: B. Hardy, N. Perreault

223. A peptide that binds GRP78 cell surface receptor on cardiomyocytes protects from ischemia induced apoptosis. **B. Hardy**, A. Raiter (Petach-Tikva, Israel) (30')
258. BMP signaling is required for proper specification of epithelial cell lineages but is not involved in development of gastric neoplasia. F. Maloum, J. Allaire, J. Morisset, J.C. Carrier, **N. Perreault** (Sherbrooke, Canada) (15')
257. Multi-step accumulation of aberrant CpG island hypermethylation in specific genes promotes development and progression of lymphomas/leukemias. **T. Oka**, H. Sato, T. Kondo, Y. Shinnou, K. Washio, I. Murakami, A. Al-Kader Lamia, X. Sun, K. Takata, M. Ouchida, K. Ohshima, M. Tanimoto, A. Utsunomiya, K. Takahashi, T. Yoshino (Okayama; Yonago; Kurume; Kagoshima, Japan) (15')
162. Gene-modified mouse bcr-abl-transformed cells expressing various immunostimulatory factors and their use as vaccines. **M. Petrácková**, E. Sobotková, M. Dusková, L. Stanek, V. Vonka (Prague, Czech Republic) (15')
252. Inhibiting tumor growth with PDL192, a humanized antibody targeting TWEAK receptor. **P.A. Culp**, D. Choi, M. Sho, M. Fox, S. Tanlimco, H. Kim, S. Ye, K. Wilson, D.T. Chao, G.C. Starling (Redwood City, CA, USA) (15')

POSTERS

WINE TASTING

POSTER VIEWING 18:30-19:30
Friday, October 8

BREAST CANCER

Room C, 09:00-11:00
Friday, October 8

Chair Persons: G. Sica, A. Patsialou, T. Lanishik Rizner

253. Epithelial/stromal crosstalk in breast cancer: Implications in cell adhesivity. **G. Sica**, C. Angelucci, G. Lama, G. Proietti, C. Fabbri, R. Masetti (Rome, Italy) (30')
242. Mechanisms of invasion in breast cancer and identification of an invasion gene signature. **A. Patsialou**, Y. Wang, J. Wyckoff, J. Lin, S. Goswami, E.R. Stanley, J.S. Condeelis (Bronx, NY, USA) (30')
264. Estrogen-metabolizing enzymes in breast cancer cell lines. **T. Lanishik Rizner**, N. Hevir, N. Trost, N. Debeljak (Ljubljana, Slovenia) (30')
209. Chromosome 17 aneusomy in breast cancer: Implications for clinical practice. **C. Marchiò**, A. Sapino (Turin, Italy) (30')

BREAST CANCER

Room C, 11:30-13:15
Friday, October 8

Chair Persons: Y. Luqmani, G.M. Calaf

140. siRNA induced loss of estrogen receptor in human breast cancer cells is associated with an epithelial to mesenchymal transition. **Y. Luqmani**, F. Al Mulla, S. Al Saleh (Kuwait) (30')
141. Effect of tyrosine kinase inhibitors is enhanced in endocrine resistant breast cancer cells displaying increased metastatic potential. **S. Al Saleh**, Y.A. Luqmani (Kuwait) (15')
192. *In vivo* and *in vitro* models for breast carcinogenesis. **G.M. Calaf** (New York, NY, USA) (30')
193. Oxidative stress and genomic instability in breast tumorigenesis. **G.M. Calaf**, A.S. Balajee, C. Echiburú-Chau, D. Roy (Arica, Chile; New York, NY, USA) (15')

BREAST CANCER

Room C, 15:00-16:30
Friday, October 8

Chair Persons: C.M. Klinge, Z. Zhong

199. COUP-TFII in tamoxifen-resistant breast cancer. **C.M. Klinge** (Louisville, KY, USA) (30')
239. *Rhizoma curcuma* exerts synthetic effect of anti-breast cancer through suppressing cell proliferation, metastasis and angiogenesis *in vitro*. **Z. Zhong**, X. Chen, K. Zhou, T. Wu, L. Cui, Y. Wang (Macau; Zhanjiang, P.R. China) (30')
124. BEX2, a novel regulator of apoptosis and cell cycle in breast cancer. **A. Naderi**, J. Liu, L. Hughes-Davies (Brisbane, Australia; Cambridge, UK) (15')
308. Apicidin inhibits human ovarian cancer cells migration and invasion via class II histone deacetylase 4 silencing. **M.Y. Ahn**, T.H. Kim, Y.J. Na, J.H. Yoon, H.S. Kim (Busan; Yangsan; Gwangju, South Korea) (15')

BREAST CANCER

Room C, 17:00-18:30
Friday, October 8

Chair Persons: D. Marchetti, R. Clarke

110. Heparanase mechanisms in brain metastatic breast cancer. L. Zhang, P. Sullivan, **D. Marchetti** (Houston, TX; Los Angeles, CA, USA) (30')
190. The unfolded protein response, and resistance to endocrine therapies in breast cancer. A. Shajahan, R. Hu, R. Riggins, C. Facey, E. Hickman, A. Zwart, Y. Wang, J. Xuan, W. Baumann, J. Tyson, **R. Clarke** (Washington, DC; Blacksburg, VA, USA) (30')
155. Breast cancer risk factors in relation with tumor associated antigenic expression in argentinian patients. **M.V. Croce**, M. Isla-Larrain, S.O. Demichelis, L. Cermignani, C.G. Alberdi, V. Ferretti, A. Segal-Eiras (La Plata; Buenos Aires, Argentina) (15')
114. Immune responses elicited in murine breast cancer model *in vivo* and 4T1 microenvironment *in vitro*. **S.S. Kumar**, A.K. Radhakrishnan, C. Soon-Keng (Kuala Lumpur, Malaysia) (15')

COLON CANCER

Room D, 09:00-11:00
Friday, October 8

Chair Persons: U. Stein, J.C. Carrier, N. Rivard

237. The metastasis inducer S100A4: Cell signaling-based interventions for reduction of colon cancer metastasis. **U. Stein**, F. Arlt, J. Smith, U. Sack, W. Walther, I. Fichtner, R.H. Shoemaker, P.M. Schlag (Berlin, Germany; Frederick, MD, USA) (30')
244. Regulation of colon cancer cell proliferation by the estrogen-related receptor alpha. G. Bernatchez, V. Giroux, T. Lassalle, **J.C. Carrier** (Sherbrooke, Canada) (30')
245. Role of PTEN in the intestinal epithelium: Implication in the control of proliferation, differentiation and cancer. M.J. Langlois, F. Boudreau, W. Chababi, C. Saucier, N. Perreault, J.C. Carrier, **N. Rivard** (Sherbrooke, Canada) (30')
103. DNA methylation of the *p14^{ARF}*, *RASSF1A* and *APC1A* genes define a poor prognosis subset of colorectal cancer patients independently of tumor stage and tumor differentiation. Z.M. Löf-Öhlin, X.-F. Sun, **T.K. Nilsson** (Örebro; Linköping, Sweden) (15')
222. Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. **Y. Shan**, X. Shen, Y. Xie, Q. Zhan (Wenzhou, P.R. China) (15')

MOLECULAR ONCOLOGY/CANCER PREVENTION

Room D, 11:30-13:15
Friday, October 8

Chair Persons: R. Gupta, H. Zhang

277. Terpenoids as potent inhibitors of cervical cancer in pre-clinical studies. **R. Gupta**, R. Munagala (Louisville, KY, USA) (30')
118. Wrap53 is an independent prognostic factor in rectal cancer - A study on Swedish rectal cancer trial. D.-W. Wang, X.-F. Sun, G. Adell, S. Mahmoudi, M. Farnebo, **H. Zhang** (Skövde; Linköping; Stockholm, Sweden) (15')
304. *In vitro* activity of a new class MMP-I in a three dimensional pancreatic cancer cell model. **A. Pries**, H. Tschesche, H.-P. Bruch, M.-L. Kruse, M. Kapischke (Hamburg, Germany) (15')
138. 5-aza-2'-deoxycytidine triggers senescence and autophagy in chronic myeloid leukemia leading to the activation of apoptotic cell death. **C. Grandjette**, M. Schneckeburger, T. Karius, J. Ghelfi, E. Henry, M. Dicato, M. Diederich (Luxembourg) (15')
221. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. **M.-T. Lee**, C.-Y. Lin, P.-H. Tsai, S.-H. Chen, L.-T. Lee, W.-T. Kao, P.-P. Lee (Taipei; Keelung, Taiwan) (15')
344. Role of the *p14^{ARF}* alterations in endometrial tumorigenesis. **A. Semczuk**, P. Olcha, K. Postawski, M. Semczuk, M. Gogacz, B. Marzec, T. Rechberger (Lublin, Poland) (15')

MOLECULAR ONCOLOGY/NITRIC OXIDE

Room D, 15:00-16:30
Friday, October 8

Chair Persons: K.N. Manola, D. Queiroz Calcagno

142. Chromosome abnormalities in chronic lymphocytic leukemia. **K.N. Manola** (Athens, Greece) (30')
173. *MYC* deregulation in gastric adenocarcinoma. **D. Queiroz Calcagno**, M.F. Leal, P. Assumpção, M. De Arruda Cardoso Smith, R.R. Burbano (Belém; São Paulo, Brazil) (30')
215. Different action of nitric oxide-modified forms of saquinavir and izoxazole derivate VGX-1027 in colon cancer cells. **D. Maksimovic-Ivanic**, S. Mijatovic, M. Mojic, G. Timotijevic, D. Miljkovic, K. Mangano, M. Donia, Y. Al-Abed, S. Stosic-Grujicic, F. Nicoletti (Belgrade, Serbia; Catania, Italy; Manhasset, NY, USA) (15')
216. Anti-melanoma potential of nitric oxide-modified form of HIV inhibitor-saquinavir; Cell specific mode of drug action. **S. Mijatovic**, D. Maksimovic-Ivanic, M. Mojic, G. Timotijevic, D. Miljkovic, K. Mangano, M. Donia, Y. Al-Abed, S. Stosic-Grujicic, F. Nicoletti (Belgrade, Serbia; Catania, Italy; Manhasset, NY, USA) (15')

MOLECULAR MEDICINE

Room D, 17:00-18:30
Friday, October 8

Chair Persons: K.S. Midwood, K. Grüngreiff

186. Regulation of inflammation by endogenous danger signals. **K.S. Midwood** (London, UK) (30')
116. Zinc in chronic hepatitis C. **K. Grüngreiff** (Magdeburg, Germany) (30')
210. Fragmented hyaluronan is an autocrine chemokinetic motility factor supported by HAS2-CD44/hyaluronidase-2 system on the plasma membrane. **K. Harigaya**, T. Saito, K. Azuma, T. Umemiya, H. Kawana, A. Toyoda, Y. Shida, M. Kitagawa (Chiba, Japan) (15')
235. A systems biology approach to the extracellular signaling pathways of acute leukemia and rhabdomyosarcoma cells. **G.I. Lambrou**, E. Koulouki, M. Adamaki, S. Vlahopoulos, M. Moschovi (Athens, Greece) (15')

COLON CANCER

Room A, 09:00-11:00
Saturday, October 9

Chair Persons: C. Paraskeva, J. Hofmanová, P. Vodicka

145. Colon cancer and COX-2: Remarkable adaptability of cancer cells to their fluctuating microenvironment. H.R. Roberts, A.M. Moore, A. Kaidi, A.C. Williams, **C. Paraskeva** (Bristol, UK) (30')
172. Molecular targeting in colorectal cancer and the role of KRAS mutation testing in the management of metastatic colorectal cancer. **M.G. McIntire** (Boston, MA, USA) (30')
168. Cellular lipid alterations during the colon adenoma-carcinoma sequence and the sensitivity to dietary fatty acids. **J. Hofmanová**, M. Ciganek, J. Slavík, N. Straková, Z. Tylichová, B. Skender, L. Kocí, M. Machala (Brno, Czech Republic) (30')
310. Various aspects addressing the susceptibility to sporadic colorectal cancer: An overview. **P. Vodicka**, B. Pardini, A. Naccarati, L. Vodicková, M. Hánová, V. Poláková, J. Slysokva, J. Hesketh, I. Tomlinson, S. Landi, R. Kumar, F. Canzian, A. Foersti, K. Hemmiki (Prague, Czech Republic; Pisa, Italy; Heidelberg, Germany; Newcastle upon Tyne; Oxford, UK) (30')

EXPERIMENTAL THERAPEUTICS

Room A, 11:30-13:00
Saturday, October 9

Chair Persons: S.A.W. Fuqua, S. Lu, A.G. Lacko

316. Novel mechanisms of hormone resistance in breast cancer. **S.A.W. Fuqua** (Houston, TX, USA) (30')
318. The EGFR/HER2-elicited multiple pathways in development, progression, and theragnosis of prostate cancer. Z. Dong, Y. Liu, J.Q. Mo, G. Boivin, L. Levin, L. Oleksowicz, **S. Lu** (Cincinnati, OH, USA) (30')
331. Reconstituted/synthetic high density lipoproteins: A novel approach for the therapeutic delivery of anti-cancer agents. **A.G. Lacko**, M. Shahzad, N. Sabnis, M. Nair, L.S. Mangala, W. McConathy, G. Lopez-Berestein, A.K. Sood (Fort Worth, TX; Houston, TX, USA) (30')

NITRIC OXIDE/CYTOKINES

Room A, 16:00-17:30
Saturday, October 9

Chair Persons: A. Niedzwiecki, C. Demonacos

315. Novel micronutrient synergy in successful control of cancer through pleiotropic mechanisms. **A. Niedzwiecki**, M.W. Roomi, N. Roomi, V. Ivanov, M. Rath (Santa Clara, CA, USA) (30')
317. Transcriptional cofactors in the regulation of energy and reactive oxygen species (ROS) production in cancer cells. Potential exploitation in cancer therapy. R. Rajendran, I. Berrou, T. Leung, K. Andreou, M. Krstic-Demonacos, **C. Demonacos** (Manchester, UK) (30')
360. The effects of the nitric oxide-modified HIV protease inhibitor Saquinavir-NO (Saq-NO) on p53-deficient androgen independent prostate cancer cell lines. **M. Donia**, D. Maksimovic-Ivanic, S. Mijatovic, M. Mojic, G. Timotijevic, D. Miljkovic, S. Caponnetto, P. Fagone, M. Libra, K. Mangano, S. Stosic-Grujicic, F. Nicoletti (Catania, Italy; Belgrade, Serbia) (15')
137. Epigenetic silencing of Polycomb target genes in multiple myeloma. **H. Jernberg-Wiklund**, A. Kalushkova, M. Fryknäs, M. Lemaire, C. Fristedt, P. Agarwal, M. Eriksson, S. Deleu, P. Atadja, A. Österborg, K. Nilsson, K. Vanderkerken, F. Öberg (Uppsala; Stockholm, Sweden; Brussels, Belgium; Cambridge, MA, USA) (15')

TUMOR BIOLOGY

Room A, 18:00-19:30
Saturday, October 9

Chair Persons: L.-G. Yu, A. Fukamizu

238. Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis. **L.-G. Yu** (Liverpool, UK) (30')
284. Cross-talk regulation of FOXO transcription factor by arginine methylation and PKB/Akt-induced phosphorylation. **A. Fukamizu** (Tsukuba, Japan) (30')
254. Stemness features in peritumor tissue of glioblastoma. **G. Sica**, G. Lama, G. Proietti, A. Mangiola, P. De Bonis, L. Lauriola, M. Jhanwar-Uniyal, G. Maira (Rome, Italy; Valhalla, NY, USA) (30')

PROSTATE CANCER

Room B, 09:00-11:00
Saturday, October 9

Chair Persons: O. Barbier, G. Perletti

206. Is glucuronidation a relevant pharmacological target in the treatment of prostate cancer? L. Grosse, S. Pâquet, A. Bélanger, **O. Barbier** (Quebec, Canada) (30')
163. Involvement of inflammation and proliferative inflammatory atrophy in prostate cancer development. **G. Perletti**, A. Vral, E. Montanari, G. Gazzano, E. Marras, V. Magri (Busto Arsizio; Milan, Italy; Ghent, Belgium) (15')
115. Prostate cancer progression: What is involved? **S. van Slambrouck**, M. Bisoffi, W. Steellant (Socorro, NM; Albuquerque, NM, USA) (15')
122. Life events, cortisol and levels of prostate specific antigen: A story of synergism. **Y. Gidron**, B. Fabre, H. Grosman, C. Nolazco, V. Mesch, O. Mazza, G. Berg (Brussels, Belgium; Buenos Aires, Argentina) (15')
269. Determination of metallothioneins and alpha-methylacyl-CoA racemase in patients with prostate carcinoma. **M. Masarik**, J. Gumulec, S. Kuchtickova, V. Kudlackova, N. Cernei, O. Zitka, P. Babula, V. Adam, S. Krizkova, R. Hrabec, A. Rovny, R. Kizek (Brno, Czech Republic) (15')
282. Anti-PSMA antibodies and recombinant fragments as agents for targeting prostate cancer. **U. Elsässer-Beile**, P. Wolf, D. Gierschner, P. Bühler, U. Wetterauer, S. Wiehr, B. Pichler (Freiburg; Tübingen, Germany) (15')
283. Highly efficient PSMAxCD3 diabody for immunotherapy of prostate cancer. **P. Bühler**, P. Wolf, K. Fortmüller, K. Alt, D. Gierschner, U. Wetterauer, U. Elsässer-Beile (Freiburg, Germany) (15')

MOLECULAR BIOLOGY/BIOTECHNOLOGY

Room B, 11:30-13:00
Saturday, October 9

Chair Persons: Y. Fan, A. Spandidos, M. Hampsey

212. Epigenetic regulation of gene expression by linker histone H1. **Y. Fan**, K. Cao, M. Magdalena, Y. Zhang (Atlanta, GA, USA) (30')
170. The PrimerBank resource of human and mouse primer pairs for PCR and QPCR. **A. Spandidos**, X. Wang, H. Wang, B. Seed (Boston, MA, USA) (30')
256. Control of eukaryotic gene expression: Gene loops and transcriptional memory. B.N. Singh, **M. Hampsey** (Piscataway, NJ, USA) (30')

EXPERIMENTAL THERAPEUTICS/MOLECULAR ONCOLOGY

Room B, 16:00-17:30
Saturday, October 9

Chair Persons: F. Nicoletti, T. Thalhammer

343. Generation of new anti-cancer compounds from nitric oxide (NO)-hybridization of protease inhibitors. Saquinavir-NO as prototypic example? S. Mijatovic, D. Maksimovic-Ivanic, M. Donia, G. Garotta, Y. Al-Abed, S. Stosic-Grujicic, **F. Nicoletti** (Belgrade, Serbia; Catania, Italy; Wilmington, DE; Manhasset, NY, USA) (30')
342. Organic anion transporting polypeptides (OATP) in hepatic tumors: Implication for tumor therapy and clinical outcome. **T. Thalhammer**, M. Svoboda, K. Wlcek, J. Riha, W. Jäger (Vienna, Austria) (30')
174. Epigenetics of multiple myeloma cells within their bone marrow microenvironment as therapeutic targets. **K. Vanderkerken**, K. Maes, S. Deleu, M. Lemaire, E. Menu, E. van Valckenborgh, T. Bos, B. van Camp, H. Jernberg-Wiklund, E. De Bruyne (Brussels, Belgium; Uppsala, Sweden) (15')
280. Apoptosis in gastrointestinal carcinoma: An immunohistochemical study for the detection of possible molecular therapeutic targets. **F. De Oliveira Lima**, H. De Oliveira Costa, L.F.M. Barrezueta, C.T.F. Oshima, J.A. Silva Jr, T.S. Gomes, N.P. Junior, R.A. Neto, M. Franco (São Paulo; Botucatu; Alagoas, Brazil) (15')

MOLECULAR ONCOLOGY

Room B, 18:00-19:30
Saturday, October 9

Chair Persons: F. Stivala, M. Libra, S. Novakovic

350. Bcl-2 rearrangement is a prognostic marker in HCV-associated diffuse large B cell lymphomas derived from MALT lymphomas. **M. Libra**, A. Zaravinos, F. Nicoletti, D.A. Spandidos, F. Stivala (Catania, Italy; Heraklion, Greece) (15')
127. Long-lasting antitumor immunity triggered by the vaccination with CpG ODNs and irradiated tumor cells. **S. Novakovic**, P. Cerkovnik, B. Jezersek Novakovic, V. Stegel (Ljubljana, Slovenia) (15')
281. GSK3 mediated c-Maf phosphorylation in multiple myeloma. **N. Herath**, N. Rocques, A. Eychène, C. Pouponnot (Orsay, France) (15')
351. Notch1 and TGFβ1 regulate the expression of FOXP3 in melanoma cell lines: Preliminary observations. **E. Skarmoutsou**, F. D'Amico, M. Libra, L. Militello, F. Stivala, M.C. Mazzarino, G. Malaponte (Catania, Italy) (15')
352. Analysis of MMP-9 gene polymorphism 1562C/T in patients suffering from systemic sclerosis with and without ulcers. **E. Skarmoutsou**, F. D'Amico, M. Marchini, G. Malaponte, F. Stivala, R. Scorza, M.C. Mazzarino (Catania; Milan, Italy) (15')
236. The impact of RNA standardization and heterogeneous gene expression on the results of cDNA array of human breast carcinoma. **M.R. Khoshnoud**, Q. He, M. Sylvan, A. Khoshnoud, M. Ivarsson, T. Fornander, J. Bergh, J. Frisell, L.-E. Rutqvist, S. Skog (Stockholm, Sweden; Shenzhen, P.R. China) (15')

GYNECOLOGICAL CANCER

Room C, 09:00-11:00
Saturday, October 9

Chair Persons: V. Dolo, U. Armato

146. Microvesicle shedding in ovarian cancer: Involvement in tumor progression. **V. Dolo**, S. D'Ascenzo, I. Giusti, A. Pavan (Rome, Italy) (30')
279. BCL10 and PKC- ζ interactions in apoptosis of human cervical carcinoma cells triggered by etoposide. A. Chiarini, M. Marconi, R. Pacchiana, **U. Armato**, I. Dal Prà (Verona, Italy) (30')
273. Endometriosis: Not a cancer but an invasive disease calling for oncological research approaches. Determination of tumour markers. **N.A. Bersinger**, B. McKinnon, M.D. Mueller (Berne, Switzerland) (30')
217. A study of confocal laser endomicroscopy for gastrointestinal neoplasm. **Y. Yang**, L. Wei, J. Huang, S. Wang, M. Li, Z. Lu, G. Sun, L. Peng, Q. Huang, E. Linghu, M. Guo (Beijing, P.R. China) (30')

CLINICAL ONCOLOGY/TUMOR BIOLOGY

Room C, 11:30-13:10
Saturday, October 9

Chair Persons: S. Pervaiz, O.T. Murray

356. Simultaneous induction of autophagy and apoptosis in cancer cells by redox dependent signals. **S. Pervaiz** (Singapore) (25')
255. Reduction of pancreatic cancer growth by phosphosulindac. **O.T. Murray**, B. Rigas (Stony Brook, NY, USA) (20')
133. Chemopreventive potential of curcumin in prostate cancer. **M.-H. Teiten**, F. Gaascht, M. Dicato, M. Diederich (Luxembourg) (15')
332. Genetic alterations in bilharzial related bladder cancer using fluorescence *in situ* hybridization. **M.S. Aly** (Jazan, Saudi Arabia) (15')
278. Roles of extracellular and intracellular sphingosine 1-phosphate in cell migration. **H. Yu**, T. Okada, M. Kobayashi, D.M. Abo-Elmatty, S. Jahangeer, S.-I. Nakamura (Kobe, Japan) (15')

INFECTIOUS DISEASES

Room C, 16:00-17:30
Saturday, October 9

Chair Persons: L.M. Junie, M. Theodoridou, M. Indrová

314. Epidemiology of MRSA - A major challenge in hospitals from Romania and Greece. **L.M. Junie**, S. Kastanakis, A. Tsouri, G. Aleuraki, A. Tsaffaraki, M. Gatzima, P. Chatziliias, E. Papadomanolaki, P. Karagianni, D. Homorodean, A. Jodal, F. Minica, A. Dascalu, R. Badila, O. Bogos, C. Ghitiu, C. Polotanu, G. Laszlo (Cluj Napoca, Romania; Chania, Greece) (30')
365. Identification of *Toxoplasma gondii* and *Hammondia hammondi* in sow abortions. A. Iovu, A. Titilincu, V. Mircean, M. Junie, **V. Cozma** (Cluj Napoca, Romania) (30')
286. Vaccination against human papilloma virus in childhood: Challenges and perspectives of contemporary research. **I.N. Mammias**, G. Sourvinos, F. Maher, D.A. Spandidos (Heraklion, Greece; Liverpool, UK) (15')
147. Mechanisms of protective immunity against MHC class I-positive and MHC class I-deficient HPV 16-associated tumours. **M. Indrová**, J. Bieblová, J. Símová, J. Bubeník, M. Reinis (Prague, Czech Republic) (15')

MOLECULAR MEDICINE

Room C, 18:00-19:30
Saturday, October 9

Chair Persons: T. Pietrangelo, S. Apostolakis, K. Umezawa

354. Molecular modification of sarcopenic skeletal muscle induced by physical activity and therapeutic approaches. **T. Pietrangelo** (Chieti, Italy) (30')
336. CXCL8 and vascular inflammation: Interactions with renin-angiotensin-system mediators and blockers. **S. Apostolakis**, K. Vogiatzi, Z. Vlata, E. Krabovitis, D.A. Spandidos (Heraklion, Greece) (15')
125. Anti-inflammatory and anticancer activities of novel NF- κ B inhibitor DHMEQ and its unique distribution in the body. **K. Umezawa** (Yokohama, Japan) (15')
126. Structure-activity relationship of NF- κ B inhibitor DHMEQ and preparation of soluble analog. **C. Shimada**, T. Saito, Y. Ishikawa, S. Nishiyama, K. Umezawa (Yokohama, Japan) (15')
112. DNA repair and the ubiquitin-proteasome system: Molecular insights into a clinically relevant association. **P.J. Vlachostergios**, A. Patrikidou, D.D. Daliani, C.N. Papandreou (Larissa, Greece) (15')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room D, 09:00-11:00
Saturday, October 9

Chair Persons: R. Gambari, G.K. Tofaris, G. Sourvinos

330. Peptide nucleic acids (PNAs) for alterations of biological activity of microRNAs. **R. Gambari** (Ferrara, Italy) (25')
333. Degradation pathways in Parkinson's disease: New insights from yeast and beyond. **G.K. Tofaris** (Oxford, UK) (25')
132. *ABCB* and *ABCC* superfamily members in resistant hepatocellular carcinoma. **X.-B. Wang**, J. Xu, S.-S. Wang, Y. Liu, M. Liu, H.-L. Li (Shiyuan, P.R. China) (25')
260. Carbon monoxide inhibits rhinovirus 14 infection via activation of guanylate cyclase in human alveolar cells. **H. Yasuda**, X. Deng, T. Sasaki, Y. Hatachi, N. Nagai, M. Yamaya (Sendai, Japan) (15')
274. Immunosuppressive pathways governing HIV-specific T cell dysfunction: The PD-1 and BATF story. **F. Porichis**, M. Quigley, F. Pereyra, J. Zupkosky, D.P. Tighe, D.S. Kwon, A. McMullen, D.G. Kavanagh, G.J. Freeman, B. Ebert, B.D. Walker, W.N. Haining, D.E. Kaufmann (Boston, MA, USA) (15')
369. Rho proteins and HCMV infection. **N. Goulidaki**, D.A. Spandidos, G. Sourvinos (Heraklion, Greece) (15')

ALTERNATIVE MEDICINE AND CANCER PREVENTION

Room D, 11:30-13:20
Saturday, October 9

Chair Persons: Y. Gidron, N. Telang, Y. Feng

117. The relationship between heart rate variability and prognosis in two cancers. C. Mouton, A. Ronson, D. Razavi, J.-M. Nougaret, F. Delhay, A. Hendliez, **Y. Gidron** (Brussels, Belgium) (25')
120. Natural phytochemicals as inhibitors of carcinogenic risk for ER-/HER-2⁺ ductal carcinoma *in situ*. **N. Telang**, M. Katdare (Montvale, NJ; New York, NY, USA) (25')
167. Interdisciplinary approaches in study of Chinese medicines: Case of coptis. **Y. Feng**, N. Wang, M. Zhu, Z. Zhang, Y. Tong, S. Tsao (Hong Kong, P.R. China) (25')
307. Predictors of therapy response in lung carcinomas. **L.R. Chirieac** (Boston, MA, USA) (20')
371. E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents. **J. Prados**, A.R. Rama, R. Ortiz, C. Melguizo, P.J. Álvarez, F. Rodríguez-Serrano, O. Caba, R. Luque, F. Hita, J.L. Ramos, M. Burgos, A. Aranega (Granada; Jaen, Spain) (15')

POSTERS

104. Medium-term oral carcinogenesis assay induced by 4NQO: Putative biomarkers involved into its pathogenesis. **D.A. Ribeiro**, A.C.C. Fracalossi, S.R. Miranda, C.T.F. Oshima (Sao Paulo, Brazil)
105. Surgical considerations in regard to Denonvilliers' fascia. **N. Furubayashi**, M. Nakamura, Y. Hori, K. Hishikawa, K.-I. Nishiyama, Y. Hasegawa (Fukuoka, Japan)
111. EphA1 receptor silencing by small interfering RNA contribute to antiangiogenic and antitumor efficacy in hepatocellular carcinoma. **G. Chen**, Y. Wang, M. Zhou, H. Shi, Z. Yu, Y. Zhu, F. Yu (Wenzhou, P.R. China)
129. CCL5 and CXCL8 gene polymorphisms and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. **S. Apostolakis**, K. Vogiatzi, K. Voudris, A. Zaravinos, S. Thomopoulou, G.E. Kochiadakis, D.A. Spandidos (Heraklion; Athens, Greece)
143. A cytogenetic study in a large series of patients with chronic lymphocytic leukemia. M. Karakosta, C. Glytsou, A. Daraki, M. Kalomiraki, P. Diamantopoulou, K. Panagiotopoulou, G.E. Pantelias, C. Sambani, **K.N. Manola** (Athens, Greece)
153. SN38, a topoisomerase I inhibitor, sensitizes X-ray-induced cell death in Balb/c 3T3 cells, but not in DNA-PK-deficient SC1K cells. T. Terado, S. Shinohara, T. Takemoto, M. Kitano, **H. Kimura** (Shiga; Kanagawa, Japan)
157. H₂O₂ induces apoptosis and synergizes with TRAIL in human melanoma cells through caspase-12 activation. **M. Tochigi**, Y. Suzuki, T. Inoue, M. Murai, M. Suzuki-Karasaki, T. Ochiai, C. Ra (Tokyo, Japan)
161. Dose finding study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for uterine cervical cancer. **K. Yamamoto** (Osaka, Japan)
169. Signaling pathways involved in glioblastoma resistance to temozolomide. **A. Carmo**, H. Carneiro, M.C. Lopes (Coimbra, Portugal)
180. Pep-19 and LPI camstatins are RNA-binding proteins. P. Saladino, C.M. Di Liegro, G. Schiera, P. Proia, A. Lo Cicero, G. Palazzolo, **I. Di Liegro** (Palermo, Italy)
181. Extracellular membrane vesicle shedding and the blood-brain barrier. G. Schiera, P. Proia, A. Lo Cicero, G. Palazzolo, E. Gucciardo, E. Ferrantelli, C.M. Di Liegro, G. Savettieri, **I. Di Liegro** (Palermo, Italy)
184. Inducible expression of transgenic dipeptidyl peptidase-IV and fibroblast activation protein alpha in an astrocytoma cell line: A tool to study their involvement in gliomagenesis. **J. Nemeckova**, P. Busek, D. Kosek, M. Hilser, K. Vlasicova, A. Sedo (Prague, Czech Republic)
191. Interferon regulatory factor-1 down-regulation promotes endurance to Fulvestrant in sensitive breast cancer cells partially via a Ras/Raf/MEK/ERK pathway. Y. Ning, R.B. Riggins, A.N. Shajahan, A. Zwart, **R. Clarke** (Washington, DC, USA; Shanghai, P.R. China)
196. Classification of glioblastomas combining copy number of chromosome 7, 9 and 10 by SNP-arrays: Impact on patient survival. **I. Crespo**, M.D. Tabernero, A.B. Nieto, O. Rebelo, H. Tão, F. Gomes, A.L. Vital, M.C. Lopes, A. Orfao (Coimbra, Portugal; Salamanca, Spain)
197. Humoral immune response against MUC1 associated with breast cancer. M.I. Larrain, A. Colussi, S.O. Demichelis, A. Segal-Eiras, **M.V. Croce** (La Plata; Buenos Aires, Argentina)
200. Tamoxifen stimulates NRF-1 transcription by activating estrogen receptor beta-DNA interaction in MCF-7 cells. **C.M. Klinge**, M.M. Ivanova (Louisville, KY, USA)

202. Potent antiproliferative activity of menadione: Sodium orthovanadate combination on human glioma cells. **Z. Delwar**, D. Avramidis, M. Cruz, Å. Siden, J.S. Yakisich (Stockholm, Sweden)
204. Intratumoral injection of pEGFC1-IGFBP7 inhibits malignant melanoma growth in C57BL/6J mice by inducing apoptosis and down-regulating VEGF expression. **R.-Y. Chen**, H.-X. Chen, P. Jian, L. Xu, J. Li, Y.-M. Fan, Y.-T. Tu (Zhanjiang; Wuhan, P.R. China)
213. Anti-diabetic berberine inhibits MCF-7 human breast cancer cell growth through a metabolic control. **W. Tan**, N. Li, S.M.Y. Lee, Y. Wang (Macau, P.R. China)
214. Analysis of p53 tumor suppressor in B-cell lymphomas. **L. Stefancikova**, B. Ravcukova, M. Moulis, P. Fabian, I. Vasova, J. Muzik, J. Malcikova, J. Smardova (Brno, Czech Republic)
224. MMP13 is a potential prognostic marker for colorectal cancer. **W.-T. Huang**, H.-J. Chang, L.-C. Yen, M.-S. Chang, S.-Y. Ho, S.-R. Lin (Pingtung, Taiwan)
225. Expression profiles of hypoxia and immune pathway-associated genes in human colorectal cancer. **M.-Y. Huang**, S.-R. Lin (Kaohsiung; Pingtung, Taiwan)
227. Identification of proteins modulated by leptin in MCF7 cells. A. Valle, **J. Sastre-Serra**, A.M. Miró, J. Oliver, P. Roca (Palma de Mallorca, Spain)
228. Measurement of PPOX and PBGD gene expression as a possible new methodology to differentiate variegate porphyria and acute intermittent porphyria. **A. Mestre-Alfaro**, M.D. Ferrer, A. Sureda, M.A. Murcia, A.M. Jiménez, J.A. Tur, A. Pons (Palma de Mallorca; Murcia, Spain)
240. Expression profiling of neuroblastoma and medulloblastoma cell lines after combined treatment by all-trans retinoic acid and LOX/COX inhibitors. **P. Chlapek**, M. Redova, K. Zitterbart, M. Hermanova, J. Sterba, R. Veselska (Brno, Czech Republic)
248. *In vitro* study of everolimus influence on HT1376 invasive bladder cancer cell line. **R. Pinto-Leite**, R. Arantes-Rodrigues, M.L. Cardoso, P.L.F. De la Cruz, L. Santos, P.A. Oliveira (Vila Real; Porto, Portugal; Lugo, Spain)
249. Efficacy of gemcitabine on invasive urinary bladder cancer 5637 cell line. R. Arantes-Rodrigues, **R. Pinto-Leite**, M.L. Cardoso, P.L.F. De la Cruz, L. Santos, A. Colaço, P.A. Oliveira (Vila Real; Porto, Portugal; Lugo, Spain)
250. mTOR inhibitors rapamycin and RAD001 in chemically induced bladder cancer. C. Vasconcelos-Nóbrega, A. Colaço, L. Santos, H. Vala, **R. Pinto-Leite**, L. Palomino, C. Lopes, P.A. Oliveira (Viseu; Vila Real; Porto, Portugal; Lugo, Spain)
263. Expression of glucose transporter GLUT-1 and GLUT-3 in human malignant gliomas and progression free survival. **S. Horn**, A. Schollmayer, B. Trumpler, W. Wagner (Mainz, Germany)
265. Automated pipetting system coupled with micro- and nanoparticles as a new tool for study of nucleic acids. **M. Masarik**, D. Huska, V. Adam, J. Hubalek, I. Provaznik, L. Trnkova, R. Kizek (Brno, Czech Republic)
266. DNA-doxorubicin interactions revealed by electrochemistry. **M. Masarik**, H. Kynclova, D. Huska, J. Hubalek, V. Adam, P. Babula, T. Eckschlager, M. Stiborova, R. Kizek (Brno; Prague, Czech Republic)
267. Square wave voltammetry as a tool for study of ellipticine-DNA interaction. **M. Masarik**, D. Huska, V. Adam, J. Hubalek, I. Provaznik, L. Trnkova, T. Eckschlager, M. Stiborova, R. Kizek (Brno; Prague, Czech Republic)
268. Level of metallothionein, glutathione and heat-stable proteins in tumours from patients with head and neck cancer. **M. Masarik**, N. Cernei, P. Majzlik, D. Huska, H. Binkova, V. Adam, R. Kizek (Brno, Czech Republic)

270. Immunological determination of serum prostate specific antigen in cancer patients and tumour cell lines - New perspective. **M. Masarik**, N. Cernei, J. Gumulec, O. Zitka, P. Babula, V. Adam, R. Kizek (Brno, Czech Republic)
271. Sarcosine as a new marker for prostate tumours. **M. Masarik**, J. Gumulec, N. Cernei, O. Zitka, P. Babula, V. Adam, R. Kizek (Brno, Czech Republic)
287. Multiple human papilloma virus (HPV) infection with novel HPV types 13 and 39 in a 5-year-old child with recurrent respiratory papillomatosis. **I. Mammias**, G. Sourvinos, E. Vakonaki, P. Giamarelou, C. Michael, A. Zaravinos, D.A. Spandidos (Heraklion; Athens, Greece)
288. Human papilloma virus (HPV) infection in childhood: Can 'high-risk' HPVs be detected in benign skin lesions in children? **I.N. Mammias**, G. Sourvinos, P. Giamarelou, C. Michael, A. Zaravinos, D.A. Spandidos (Heraklion; Athens, Greece)
289. Human papilloma virus and recurrent respiratory papillomatosis in children in Greece: A retrospective study. **I.N. Mammias**, G. Sourvinos, P. Giamarelou, E. Vakonaki, C. Michael, A. Zaravinos, D.A. Spandidos (Heraklion; Athens, Greece)
290. Hydroxylation of synthetic methoxylated analogues of the chemopreventative agent resveratrol alters their antiproliferative activity. **V.P. Androutsopoulos**, K. Ruparelia, R.R. Arroo, H. Filippakis, D.A. Spandidos, A.M. Tsatsakis (Heraklion, Greece; Leicester, UK)
291. Citrus flavonoid nobiletin induces CYP1-enzyme activity and CYP1-mediated oxidative metabolism in MCF-7 breast adenocarcinoma cells. **V.P. Androutsopoulos**, S. Surichan, R.R.J. Arroo, M.R. Boarder (Leicester, UK)
292. Genetic variability of the distal promoter of the ST2 gene in coronary artery disease. A. Tsapaki, **A. Zaravinos**, S. Apostolakis, K. Vogiatzi, K. Voudris, G.E. Kochiadakis, D.A. Spandidos (Heraklion, Greece)
293. Measurement of the plasma cell-free DNA levels in heart failure using the β -globin gene as a marker. **A. Zaravinos**, S. Tzoras, S. Apostolakis, K. Lazaridis, D.A. Spandidos (Heraklion; Athens, Greece)
294. *IGF2* and *H19* promoter methylation is not correlated with expression of the genes in placentas complicated by fetal growth restriction. **A. Zaravinos**, O. Koukoura, S. Sifakis, S. Apostolidou, M. Widschwendter, D.A. Spandidos (Heraklion, Greece; London, UK)
295. Loss of imprinting and gene expression analysis of the genes H19 and IGF2 in urinary bladder cancer. **A. Zaravinos**, D. Delakas, D.A. Spandidos (Heraklion; Athens, Greece)
296. Expression profiling of bladder carcinoma. An investigation using cDNA microarrays and GEO computational analysis. **A. Zaravinos**, G.I. Lambrou, I. Boulalas, D. Delakas, D.A. Spandidos (Heraklion; Athens, Greece)
297. VEGFA and FGF2 involvement in the pathogenesis of the pterygium. **A. Zaravinos**, E.T. Detorakis, D.A. Spandidos (Heraklion, Greece)
298. Involvement of *PEBP1/RKIP* and *BRAF* in the pathogenesis and progression of urinary bladder cancer. **A. Zaravinos**, D. Delakas, D.A. Spandidos (Heraklion; Athens, Greece)
299. Spotlight on differentially expressed genes in urinary bladder cancer vs. healthy tissue, as well as in invasive vs. superficial tumours. **A. Zaravinos**, G.I. Lambrou, I. Boulalas, D. Delakas, D.A. Spandidos (Heraklion; Athens, Greece)
300. Expression profiles of YY1 and CDKIs in urinary bladder cancer: Correlation with survival. **A. Zaravinos**, D. Volanis, D. Delakas, D.A. Spandidos (Heraklion; Athens, Greece)
301. GEO computational analysis regarding the expression of Yin Yang 1 in human tumors. **A. Zaravinos**, D.A. Spandidos (Heraklion, Greece)

302. Decreased hPGH and IGF-1 expression levels in IUGR-associated placentas. M. Koutsaki, **A. Zaravinos**, S. Sifakis, D. Koutroulakis, D.A. Spandidos (Heraklion, Greece)
303. Expression analysis of the Rho kinases in urinary bladder cancer. D. Volanis, **A. Zaravinos**, T. Kadiyska, V. Zoumpourlis, D. Delakas, D.A. Spandidos (Heraklion; Athens, Greece)
313. Semi-automated micronucleus-centromere scoring in assessing cellular damage in patients exposed to low doses of ionizing radiation. A. Baeyens, J.P. Slabbert, R. Swanson, H. Thierens, P. Willem, **A. Vral** (Somerset West; Johannesburg, South Africa; Ghent, Belgium)
319. Biological effects of potassium tellurite in *Corynebacterium diphtheriae* strains. L.S. Dos Santos, P.S. Sabbadini, D.L.R. Gomes, G.A. Batista, C.S. Dos Santos, M.C. Souza, L. De O. Moreira, A.C. Rosa, G.A. Pereira, R.H. Junior, L.M.B. De O. Asad, **A.L. De Mattos-Guaraldi** (Rio de Janeiro, Brazil)
320. Molecular and phenotypic characterization of *Corynebacterium diphtheriae* strains at a comprehensive cancer center. C.A. De Souza Martins, G.A. Pereira, G.A. Batista, L.S. Dos Santos, M.C. De Souza, C.S. Dos Santos, D.L.R. Gomes, L.M.D. De Faria, R.H. Júnior, **A.L. De Mattos-Guaraldi** (Rio de Janeiro, Brazil)
321. Effects of meloxicam, lornoxicam, alone and in combination with chemotherapeutic agents on the RAF/MEK/ERK pathway in Raji cells. **H.I. Onen**, A. Yilmaz, E. Alp, A.S. Yar, E. Konac, S. Menevse (Ankara, Turkey)
322. The pan deacetylase inhibitor panobinostat inhibits growth of human Burkitt's lymphoma cell line (Raji). **H.I. Onen**, I. Dogan, V. Ergin, E. Konac, A. Ekmekci, A. Menevse (Ankara, Turkey)
323. Investigating apoptotic and epigenetic effects of mevastatin and 5-aza-2'-deoxycytidine in HL-60 cell line. **A. Yilmaz**, E. Alp, E. Konac, S. Menevse (Ankara, Turkey)
324. Investigating anti-angiogenic and apoptotic effects of Bevacizumab in breast cancer cell line. E. Alp, **A. Yilmaz**, E. Konac, S. Menevse (Ankara, Turkey)
325. Mithramycin-mediated induction of K562 cell erythroid differentiation is associated with inhibition of the mTOR-C1 pathway. N. Bianchi, A. Finotti, C. Zuccato, E. Fabbri, M. Borgatti, **R. Gambari** (Ferrara, Italy)
326. A *Saccharomyces cerevisiae* model suitable for screening of correctors of stop-codon mutations. M. Borgatti, A. Finotti, F. Salvatori, M. Lipucci, G. Breveglieri, C. Zuccato, N. Altamura, **R. Gambari** (Ferrara; Pisa; Bari, Italy)
327. Surface plasmon resonance imaging (SPR-I), peptide nucleic acid (PNA) probes and nanoparticle-enhancement for PCR-free ultrasensitive detection of β -thalassemia mutations in human genomic DNA. R. D'Agata, G. Breveglieri, L. Zanoli, M. Borgatti, G. Spoto, **R. Gambari** (Catania; Ferrara, Italy)
328. Inhibition of microRNA 210 biological activity with an anti-miR-210 peptide nucleic acid. E. Fabbri, N. Bianchi, E. Brognara, A. Finotti, G. Breveglieri, M. Borgatti, A. Manicardi, R. Corradini, R. Marchelli, **R. Gambari** (Ferrara; Parma, Italy)
329. Generation and molecular characterization of a transgenic mouse line carrying a mutated human IVS-I-6 thalassemia β -globin gene. A. Finotti, G. Breveglieri, I. Mancini, N. Bianchi, I. Lampronti, F. Salvatori, G. Feriotto, C. Zuccato, M. Borgatti, G. Carandina, C. Melandri, F. Altruda, S. Fagoonee, M. Iannicella, L. Breda, S. Rivella, **R. Gambari** (Ferrara; Turin, Italy; New York, NY, USA)
334. MSM suppresses tumor growth via inhibition of angiogenesis in breast cancer. **Y.M. Yang**, E.-J. Lim, J.-H. Park, Y.-H. Joung, F. Kwon (Seoul, Korea)
337. mRNA expression profile of the *Akt* family genes, *SDF1* and *CXCR4*, in human brain gliomas. **R. Lymbouridou**, G. Soufla, A.M. Chatzinikola, A. Vakis, D.A. Spandidos (Heraklion, Greece)

339. Expression of HDAC1-3 in endometrial cancer. **V. Androutsopoulos**, S. Sifakis, E. Vakonaki, D. Koutroulakis, G. Koutoulakis, A. Pitarokoilis, D.A. Spandidos, A.M. Tsatsakis (Heraklion, Greece)
345. Expression levels of NAG-1, P-gp and NF- κ B genes in nasal polyp tissue. **V. Ergin**, M. Duzlu, A. Menevse, F. Ileri (Ankara, Turkey)
346. CD20 mutation is associated with resistance to rituximab in a subset of patients with B-cell non-Hodgkin lymphoma. **M. Libra**, M.N. Terzo, L. Militello, A.E. Russo, G. Ligresti, M. Russo, F. Nicoletti, F. Stivala, B. Bonavida, S. Travali (Catania; Taormina, Italy; Los Angeles, CA, USA)
347. BRAF G469S mutation as indicator of neoplastic transformation in workers with UV exposure. **A. Marconi**, M. Libra, M. Claudio, S. Travali, L. Proietti, J.A. McCubrey, G. Malaponte (Catania, Italy; Greenville, NC, USA)
348. Osteopontin/matrix metalloproteinases pathway is not activated in cervical carcinoma. **N. Vella**, A. Zaravinos, M. Libra, S. Candido, A. Scalisi, F. Nicoletti, M.C. Mazzarino, D.A. Spandidos, F. Stivala (Catania, Italy; Heraklion, Greece)
349. Correlation between neutrofil associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) levels in hepatocellular carcinoma development. **F.M. Pezzino**, N. Vella, M. Libra, M. Cervello, G. Montalto, S. Travali, F. Stivala (Catania; Palermo, Italy)
357. A novel DHCR7 mutation in a Smith-Lemli-Opitz Syndrome in a Sicilian newborn. **A. Russo**, F.L. Carbone, V. Tummino, M. Lia, M.L. Incremona, L. Amodeo, L. Maiorana, G. Barrotta, A. Calderone, A. Brogna, L. Mannino, S. Travali (Catania, Italy)
358. A novel mutation of the MSH2 gene in a Sicilian Family with HNPCC syndrome. **F.L. Carbone**, A. Russo, M.N. Terzo, C. Di Mauro, V. Tummino, F.M. Pezzino, S. La Rosa, M. Lia, M.L. Incremona, V. Vasta, S. Travali (Catania, Italy)
359. New molecular approaches to characterize DAZ genes. **F.M. Pezzino**, S. La Rosa, A. Biondi, M.N. Terzo, C. Di Mauro, L. Amodeo, G. Romeo, L. Maiorana, A. Brogna, V. Vasta, G. Barrotta, A. Calderone, G.L. D'Amico, S. Travali (Catania, Italy)
362. Prevalence of polyomaviruses and RAS family oncogenes mutations in human pancreatic cancer. **V. Balis**, N. Soultziz, G.P. Stathopoulos, D.A. Spandidos (Heraklion; Athens, Greece)
363. The presence of human herpes virus 8 in semen impairs sperm count and motility. **E. Neofytou**, N. Soultziz, G. Sourvinos, M. Asmarianaki, D.A. Spandidos, A. Makrygiannakis (Heraklion, Greece)
364. Association of CX3CR1 V249I and T280M polymorphisms with benign prostatic hyperplasia and prostate cancer. **K. Papadimitriou**, N. Soultziz, S. Apostolakis, D.A. Spandidos (Heraklion, Greece)
366. Epidemiological studies concerning cryptosporidiosis species in calves in the center and northwest regions of Romania. A. Bejan, A. Iovu, V. Mircean, C. Magdas, **V. Cozma** (Cluj Napoca, Romania)
368. Methylation and expression profile of p73 in endometrial carcinoma. **E. Vakonaki**, N. Soultziz, D. Papadogianni, S. Sifakis, D.A. Spandidos (Heraklion, Greece)